Phase II study on ET-743 in BRCA1 and BRCA2 mutation carrier and BRCAness phenotype advanced ovarian cancer patients
Phase of Trial: Phase II
Latest Information Update: 04 Oct 2016
At a glance
- Drugs Trabectedin (Primary)
- Indications Ovarian cancer
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms MITO 15
- Sponsors PharmaMar
- 04 Oct 2016 Last checked against European Clinical Trials Database record.
- 01 Oct 2016 Status changed from active, no longer recruiting to completed.
- 17 Dec 2015 Results published in the Annals of Oncology